Brazikumab (AMG 139) is a humanized antibody targeting IL-23 by binding to the P19 subunit. It is a selective IL23p19 antagonist and can be used in Crohns disease research.
Purity:
95.00%
CAS Number:
[1610353-18-8]
Target:
Interleukin|||IL Receptor
* VAT and and shipping costs not included. Errors and price changes excepted